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The impact of implant-related 
infections in orthopaedics and 
trauma
The biomaterials and medical devices indus-
try has experienced rapid growth in recent 
decades, thanks to technological advances 
and a sustained clinical demand. The industry 
is projected to maintain a compound annual 
growth rate of approximately 10% over the 
next ten years, with orthopaedics and cardio-
vascular surgery continuing to lead the mar-
ket worldwide.1,2
according to a recent report, approxi-
mately 1.5 million joint arthroplasties are 
performed annually in Europe,3 while the 
prevalence of individuals with a hip or knee 
prosthesis in the United States is around 
seven million.4 osteosynthesis for long bone 
fractures shows a similar impact, with around 
270 000 new implants inserted each year in 
France, or 403 per 100 000 people.5 This is 
comparable to the 395 joint arthroplasties 
performed each year per 100 000 people in 
the same country.3
although the application of implanting 
biomaterials is becoming more common, 
their long-term durability is not guaranteed, 
and infection remains one of the main rea-
sons for early failure in orthopaedics and 
trauma. Despite the introduction of routine 
systemic antibiotic prophylaxis administra-
tion, as well as improved surgical facilities 
and procedures, prosthetic joint infection 
(PJI) affects between 0.5% and 15% of 
patients undergoing primary or revision 
joint arthroplasty, when considering high-
risk and oncological cases;6,7 these figures 
may be underestimated.8 Surgical site infec-
tion (SSI) after internal osteosynthesis for 
closed fracture has a reported incidence 
ranging from 0.5% to 10%,9-12 and up to 
50% after open fractures.13 Post-surgical 
infection following spine surgery occurs in 
1% to 14% of patients, depending on the pre-
operative diagnosis and type of surgery;14,15 
similar figures are reported for a variety of 
 surgical procedures involving implantable 
devices in orthopaedics and trauma.16-18
Antibacterial coating of implants:  
are we missing something?
Implant-related infection is one of the leading reasons for failure in orthopaedics and 
trauma, and results in high social and economic costs. Various antibacterial coating tech-
nologies have proven to be safe and effective both in preclinical and clinical studies, with 
post-surgical implant-related infections reduced by 90% in some cases, depending on the 
type of coating and experimental setup used. economic assessment may enable the cost-
to-benefit profile of any given antibacterial coating to be defined, based on the expected 
infection rate with and without the coating, the cost of the infection management, and the 
cost of the coating. After reviewing the latest evidence on the available antibacterial coat-
ings, we quantified the impact caused by delaying their large-scale application. considering 
only joint arthroplasties, our calculations indicated that for an antibacterial coating, with a 
final user’s cost price of €600 and able to reduce post-surgical infection by 80%, each year 
of delay to its large-scale application would cause an estimated 35 200 new cases of post-
surgical infection in europe, equating to additional hospital costs of approximately €440 
million per year. An adequate reimbursement policy for antibacterial coatings may benefit 
patients, healthcare systems, and related research, as could faster and more affordable regu-
latory pathways for the technologies still in the pipeline. This could significantly reduce the 
social and economic burden of implant-related infections in orthopaedics and trauma.
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The economic and social costs of implant-related 
infections are significant,19-22 with high morbidity and a 
possible increase in mortality.10 In particular, direct hos-
pital costs, related to the management of PJI, range from 
approximately €20 000 to €60 000 (Table I),23-31 while 
the long-term economic effect of post-surgical infection 
after joint arthroplasty has been calculated to exceed 
$390 000 per case.
Antibacterial coating in orthopaedics and 
trauma
Every time a biomaterial is implanted, a competition 
between the host and the bacteria occurs for surface col-
onization. In the event of bacterial adhesion to an implant, 
immediate biofilm formation starts, making the bacteria 
extremely resistant to the host’s defence mechanisms 
and antimicrobials.32-34 In fact, fully formed biofilms are 
found a few hours after the first bacterial adhesion on a 
substrate,35,36 thus, importantly, the destiny of an implant 
is decided at the time of surgery. Hence, all efforts should 
be directed to create, at the time of surgery and implant 
application, a local environment favourable to the host 
and hostile to the microorganisms.
This observation explains why short-term systemic 
antibiotic prophylaxis is equally as effective as long-term 
prophylaxis,37 and forms the basis for local protection of 
biomaterials through suitable antibacterial coating or fin-
ishing technologies.38,39 Based on their mechanism of 
action, antibacterial coatings have been classified as fol-
lows (Table II).40
Passive surface finishing/modification: this strategy is 
aimed at preventing or reducing bacterial adhesion to 
implants through surface chemistry and/or structure 
modifications, without the use of any pharmacologically 
active substance. Examples of this approach include 
modified titanium dioxide surface or polymer coatings.
active surface finishing/modification: with this strat-
egy, pharmacologically active pre-incorporated bacteri-
cidal agents, such as antibiotics, antiseptics, metal ions, 
or other organic and inorganic substances, are actively 
released from the implant in order to reduce bacterial 
adhesion. Examples of this approach are ‘contact killing’ 
active surface with silver- or iodine-coated joint implants.
Perioperative antibacterial local carriers or coatings: this 
strategy employs local antibacterial carriers, or coatings, 
that are not built into the device, but rather are applied 
during surgery, immediately prior to the insertion of the 
implant. They may have direct or synergistic antibacterial/
Table I. Economic impact of prosthetic joint infection (PJI). Different values for similar pathological conditions reflect the variability of the costs across coun-
tries, the heterogeneous methodologies used for calculation, and the different strategies adopted for infection management
Author country condition economic analysis performed cost
Klouche et al23 (2010) France Hip PJI Hospital costs for revision surgery €23 757
Haenle et al24 (2012) Germany Knee PJI Hospital costs for revision surgery €25 195
lieb et al25 (2015) Germany Knee PJI Hospital costs for revision surgery €19 946
Romanò et al29 (2010) Italy Hip PJI Hospital costs for revision surgery €60 394
alp et al27 (2016) Turkey Hip and knee PJI Hospital costs for revision surgery $16 999
vanhegan et al26 (2012) United Kingdom Hip PJI Hospital costs for revision surgery £21 937
Kamath et al28 (2015) United States Hip PJI Hospital costs for revision surgery $31 753
 Knee PJI Hospital costs for revision surgery $25 692
Kurtz et al20 (2012) United States Hip PJI Hospital costs for revision surgery $30 300
 Total hospital charges for revision surgery $93 600
 Knee PJI Hospital costs for revision surgery $24 200
 Total hospital charges for revision surgery $74 900
Parisi et al30 (2017) United States Hip PJI long-term economic effect as per Markov utility model $390 806
Brochin et al31 (2018) United States Hip PJI Hospital costs for revision surgery $31 312
Table II. Classification of antibacterial implant protection strategies40
features/examples Development  
stage
Passive surface finishing/modifications  
Prevention of bacterial adhesion  
Hydrophilic surface Preclinical
Superhydrophobic surface Preclinical
anti-adhesive polymers Preclinical
Nanopatterned surface Preclinical
albumin Preclinical
Hydrogels Preclinical
Biosurfactants Preclinical
Active surface finishing/modifications  
Inorganic  
Silver ions and nanoparticles Market
other metals (copper, zinc, titanium dioxide, etc.) Preclinical
Non-metals: iodine Clinical
other non-metal ions (selenium, graphene, etc.) Preclinical
Organic  
Coated/linked antibiotics Market
Covalently linked antibiotics Preclinical
antimicrobial peptides Preclinical
Cytokines Preclinical
Enzymes and biofilm-disrupting agents Preclinical
Chitosan derivatives Preclinical
Synthetic  
Non-antibiotic antimicrobial compounds Preclinical
‘Smart’ coatings Preclinical
Combined  
Multilayer coating Preclinical
Perioperative antibacterial local carriers or 
coatings
 
Non-biodegradable  
antibiotic-loaded poly(methyl methacrylate) Market
Biodegradable  
antibiotic-loaded bone grafts and substitutes Market
Fast-resorbable hydrogel Market
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anti-adhesive activity or may deliver high local concentra-
tions of loaded antibiotics or antibacterials.
Translating preclinical research to clinical application 
is particularly challenging, time-consuming, and expen-
sive. as a result, many promising coating technologies 
that show clear efficacy and safety in the preclinical set-
ting fail to reach the market.41 Besides local antibiotic 
carriers such as antibiotic-loaded poly(methyl meth-
acrylate) (PMMa), bone grafts, and bone substitutes that 
were not specifically designed to act as antimicrobial 
coatings of implants, only four technologies are cur-
rently available in orthopaedics and trauma for clinical 
use, or at least with reported clinical results.42 These are 
silver and iodine coatings, gentamicin poly(D, l-lactide) 
(Plla) coating, and a fast-resorbable hydrogel coating 
composed of covalently linked hyaluronan and Plla 
(Defensive antibacterial Coating (DaC); Novagenit Srl, 
Mezzolombardo, Italy) (Fig. 1) (Table III).
Silver coatings. Silver antibacterial activity is well known, 
and mostly depends on the ability of dissolved cations 
to interfere with bacterial cell membrane permeability 
and cellular metabolism. Moreover, when released in an 
aqueous medium, silver cations also contribute to the for-
mation of reactive oxygen species and other mechanisms 
that potentially influence prokaryotic cells.43 Different 
technologies are currently used to apply the silver coat-
ing to metallic orthopaedic implants.42,44 Comparative 
and prospective studies are lacking; only retrospective 
case series have been published, with coating application 
restricted to tumour prostheses.45,46
a retrospective case-control study was recently pub-
lished by wafa et al47 that reported the results of silver-
coated tumour prostheses in 85 patients compared with 
85 matched control patients treated between 2006 and 
2011. Indications included 50 primary reconstructions 
(29.4%), 79 one-stage revisions (46.5%), and 41 two-
stage revisions for infection (24.1%). at a minimum fol-
low-up of 12 months, comparing the matched silver-free 
control group with the silver-coated mega-endoprosthe-
sis group, there was a significant reduction in the overall 
postoperative infection rate from 22.4% to 11.8% 
(p = 0.03) in favour of the silver-coated implant group, 
with a mean reduction of approximately 48% in infection 
rate.
Despite these results, the routine use of silver-coated 
implants remains rather limited for several reasons. The 
main concerns have been about the toxicity of silver ions; 
the same activity that interferes with prokaryotic cells 
could also interfere with eukaryotic cells, exerting cyto-
toxicity on bone cells, while the silver ions released could 
accumulate and cause harm in distant locations within 
the body.48 another limitation is the incomplete protec-
tion of the implant, since the intramedullary part of the 
prosthesis and some modular components of the implant 
(including the acetabular component and the polyethyl-
ene insert) cannot be coated. Moreover, only a few 
implant designs are offered with silver coating protec-
tion, while the cost of the technology remains quite high 
when considering applications outside oncology.49
Iodine coating. Povidone-iodine can be used as an 
electrolyte, resulting in the formation of an adhesive, 
porous anodic oxide with the antiseptic properties 
of iodine.50 Besides extensive preclinical studies,50-52 
excellent clinical efficacy was reported for iodine 
coating of titanium alloys in a continuous, non- 
comparative series of 222 patients.53 Preoperative diag-
noses included tumour in 95 cases (42.8%), 34 limb 
deformities (15.3%), 29 cases of degenerative disease 
(13.1%), 27 cases of osteomyelitis (12.2%), 24 non-
unions (10.8%), and 16 fractures (7.2%). a variety of 
implants were used: 82 spinal instrumentations, 55 
plates for osteosynthesis, 36 external fixations (pins and 
wires), 32 tumour prostheses, ten hip prostheses, four 
knee prostheses, two nails, and one cannulated screw. at 
a mean follow-up of 18.4 months (3 to 44), acute infec-
tion developed in three tumour cases (1.9%).
Two more recent non-comparative studies – one 
investigating iodine coating and megaprosthesis,54 the 
other investigating total hip arthroplasty (THa)55 – 
 confirmed the safety and efficacy of the technology at 
longer follow-ups. Based on these findings, clinical trials 
are currently ongoing to meet the regulatory require-
ments for market approval. while no adverse event has 
been reported to date, the longer-term effects of local 
application of iodine coating and the application to mate-
rials other than titanium are yet to be assessed.
Gentamicin PLLA coating. approximately a decade ago, 
the gentamicin Plla matrix coating for tibial nails was 
Fig. 1a  Fig. 1b  Fig. 1c
Examples of antibacterial coating of joint prosthesis: a) silver-coated hip tumour prosthesis; b) iodine-coated tumour prosthesis; c) vancomycin-loaded Defen-
sive antibacterial Coating (DaC) hydrogel, applied at surgery on an acetabular titanium component.
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first introduced into clinical use in Europe. The coating, 
based on a fully resorbable Plla matrix with gentamicin 
sulphate, provides 80% release of the antibiotic within 
the first 48 hours.56 In the first published clinical report, 
Fuchs et al57 observed no deep infections at six months’ 
follow-up in 21 patients treated with a UTN PRotect 
Tibial Nail (DePuy Synthes, Bettlach, Switzerland) for 
closed or open tibial fractures, as well as for revisions. 
Furthermore, Metsemakers et  al58 reported a retrospec-
tive analysis, including nine patients with a Gustilo and 
anderson grade II or grade III open tibial fracture, four 
infected nonunions, two acute tibial shaft fractures pre-
treated with external fixation, and one aseptic nonunion 
with a soft-tissue defect. at 18 months’ follow-up, no 
implant-associated deep infection was reported. Finally, 
the most recent and largest study, using data from four 
centres, analyzed the outcome of 99 patients with fresh 
open or closed tibial fractures or undergoing nonunion 
revision surgery.59 at 18 months’ follow-up, deep sur-
gical site infection or osteomyelitis was noted in 4/55 
patients (7.2%) after fresh fracture and in 2/26 patients 
(7.7%) after revision surgery. The heterogeneous mate-
rial and the lack of a comparator makes the interpretation 
of these results particularly difficult.
a limit of this technology is the fact that it is only avail-
able for the tibia and for one specific nail design. 
Furthermore, screws and fixation holes are not protected 
by the coating, while gentamicin resistance, ranging 
from 2% to 50% in Europe,60 may reduce the efficacy of 
the coating in some cases.
DAc hydrogel. DaC hydrogel is the first antimicrobial 
coating specifically designed to protect implanted bio-
materials in orthopaedics, traumatology, dentistry, and 
maxillofacial surgery.61,62 The device is based on pre-
vious observations of the ability of hyaluronic-based 
compounds to reduce bacterial adhesion and biofilm 
formation, and to protect against various infectious 
agents.63-68 In line with these observations, significant 
reductions of adhering bacteria on sterile titanium discs, 
coated with DaC hydrogel, were observed after 15, 30, 
60, and 120 minutes of incubation.62
although designed as a stand-alone product, the DaC 
hydrogel has demonstrated itself to be capable of entrap-
ping several antibacterial agents at concentrations ranging 
from 2% to 10%, released locally for up to 72 hours, with 
an amount of drug released that is hundreds or thousands 
of times higher than the minimum inhibitory concentra-
tion (MIC), in a time- and dose-dependent manner.61
The safety and efficacy of DaC hydrogel have been 
investigated in animal studies that showed the ability of 
the antibiotic-loaded hydrogel to prevent implant-related 
infection significantly with69 and without70 systemic anti-
biotic prophylaxis. In a further study, focusing on the 
impact on bone healing and implant osteointegration, 
no detrimental effects were noted in vancomycin-loaded 
DaC-coated implants.71
In the first large multicentre randomized prospective 
clinical trial, a total of 380 patients were included who 
were scheduled to undergo primary (n = 270), revision 
(n = 110), total hip (n = 298), or total knee (n = 82) joint 
arthroplasty with a cementless or a hybrid (partially 
cemented) implant.72 The patients were randomly 
assigned, in six European orthopaedic centres, to receive 
an implant with the DaC coating, intraoperatively loaded 
with antibiotics, or without the coating (control group). 
overall, 373 patients were available at a mean follow-up 
of 14.5 months (sd 5.5). a total of 11 SSIs were observed 
in the control group, with only one observed in the treat-
ment group (6% vs 0.6%; p = 0.003). No local or systemic 
side effects related to the DaC hydrogel coating were 
Table III. Comparison of clinically available antimicrobial coating technologies specifically designed for orthopaedics and trauma implants
factor Silver Iodine Gentamicin poly(D, 
L-lactide) matrix
Hyaluronic acid and 
poly(D, L-lactide) hydrogel
Regulatory phase Market Clinical trials Market Market
Trademark and 
manufacture 
company
agluna (accentus Medical 
ltd, Didcot, United Kingdom); 
Mutars (Implantcast GmbH, 
Buxtehude, Germany); Porag 
(waldemar link GmbH & Co. 
KG, Hamburg, Germany)
Not applicable UTN PRotect Tibial Nail (DePuy 
Synthes, Bettlach, Switzerland); 
Expert Tibial Nail (ETN) PRotect 
(DePuy Synthes, Johnson & 
Johnson, New Brunswick, New 
Jersey)
Defensive antibacterial 
Coating (DaC) (Novagenit Srl, 
Mezzolombardo, Italy)
Mechanism of action Silver ion release Iodine release Gentamicin release antifouling activity with 
ancillary antibiotic release
Main applications Tumour mega-prosthesis Titanium implants including 
spine instrumentation, hip and 
knee joint arthroplasties, plates 
and screws
Tibial nail for the treatment of 
tibial fractures and nonunions
orthopaedics, traumatology, 
dentistry, and maxillofacial 
implants
Main limitations only available for some 
tumour prostheses; lack of 
prospective, comparative 
studies; incomplete implant 
protection (may only be applied 
to the extramedullary part of 
the implant and may only be 
applied to metallic substrate); 
possible ion toxicity
Not available on the market; 
lack of comparative studies; 
incomplete implant protection 
(lack of data on the application 
to materials other than 
titanium); lack of data on long-
term safety
only available for one specific 
application; lack of prospective, 
comparative studies; 
incomplete implant protection 
(fixation screws and screw holes 
not protected; may not work 
against gentamicin-resistant 
strains)
Clinical trials only available 
for primary and revision joint 
arthroplasty and internal 
osteosynthesis for closed 
fractures; lack of long-term 
studies; may not prevent late 
haematogenous infection
203aNTIBaCTERIal CoaTING oF IMPlaNTS: aRE wE MISSING SoMETHING? 
vol. 8, No. 5, May 2019
reported, and no detectable interference with implant 
osteointegration was noted.
In another multicentre prospective study, 256 patients 
undergoing osteosynthesis for a closed fracture were ran-
domly assigned, in five European orthopaedic centres, to 
receive the antibiotic-loaded DaC coating or to a control 
group without coating. at a mean follow-up of 18.1 
months (sd 4.5), six SSIs (4.6%) were observed in the 
control group compared with none in the treated group 
(p < 0.02). No local or systemic side effects related to DaC 
hydrogel coating were observed, and no detectable 
interference with bone healing was reported.73 However, 
it should be noted that, although the mean follow-up 
period was over 1.5 years, this is relatively short from the 
point of view of osseointegration and implant survival.
More recently, DaC hydrogel-coated cementless one-
stage exchange for infected prosthesis showed similar 
results when compared with a retrospective series of 
matched controls treated with two-stage revision with-
out the coating. No difference in the rate of infection 
recurrence was observed at a minimum follow-up of two 
years.74 In line with these findings, in another case- 
control study, at a mean follow-up of 2.7 years (2.1 to 
3.5), cementless two-stage hip revision for infected cases 
showed no evidence of infection recurrence, implant 
loosening, or adverse events in the DaC-treated group, 
compared with four cases of infection recurrence in the 
control group.75 However, as previously noted,72 longer-
term data are required to examine delayed or late pros-
thetic joint infections. In fact, while the quick resorption 
of the hydrogel makes long-term side effects quite 
unlikely, this same feature may limit or prevent the abil-
ity of this technology to protect the implant from late, 
haematogenous infections.
effects of delaying the routine use of antibacterial coat-
ings. Graves et al76 have demonstrated that implement-
ing measures against post-surgical infection after joint 
arthroplasty results in a measurable reduction of PJI, 
with considerable cost-saving and improved quality of 
life. according to their simulation, considering a cohort 
of 77 321 patients undergoing primary THa, a combined 
treatment strategy able to reduce post-surgical infection 
(odds ratio (oR) 0.13) may prevent 1481 cases of deep 
infection, leading to annual cost savings of £8 325 277 
when compared with a baseline strategy (plain cement, 
conventional ventilation, and no systemic antibiotics).
Shearer et al77 calculated that the net monetary ben-
efit resulting from a 10% reduction in PJIs was $278 per 
index procedure, and concluded that strategies aimed 
at reducing PJI may have a greater effect on cost and 
long-term effectiveness of THa than further enhance-
ments in implant longevity.
our group recently described an algorithm to calculate 
the cost-effectiveness of different antibacterial coating 
strategies applied to joint prostheses, taking both direct 
and indirect hospital costs into account.49 according to 
this model, an antibacterial coating technology able to 
reduce post-surgical infection by 80%, at a cost per 
patient of €600, would provide a reduction in hospital 
costs of €200 per patient if routinely applied in a popula-
tion that would otherwise have an expected post-surgical 
infection rate of 2% (Table Iv). Projecting these figures at 
a European level, with approximately 2.2 million joint 
arthroplasties performed per year,3 we may speculate 
that a year of delay in the routine use of such a coating 
would result in 35 200 additional PJI cases per year with 
additional annual costs of approximately €440 million 
per year. These calculations do not include any costs that 
might result from an increased mortality rate, permanent 
disability deriving from post-surgical infection, or poten-
tial medicolegal claims.
In conclusion, implant-related infections have a pro-
nounced social and economic impact,78 with increased 
rates of morbidity and mortality.79 Unless novel, effective 
measures are taken to reduce the incidence of SSIs, these 
complications will become a growing burden to health-
care systems over the coming decades.80,81 Despite the 
recognized need for implant-related infection contain-
ment and the demonstrated efficacy of some antibacte-
rial coatings notwithstanding, only a few technologies 
are currently available in orthopaedics and trauma. In 
fact, while some potentially effective solutions are found 
not suitable for orthopaedic implants, due to cytotoxic-
ity, immunoreactivity, or interference with bone healing 
and osteointegration, those successfully tested in vitro 
and in vivo may still be unable to reach large scale clinical 
application, due to biotechnological, economic, and reg-
ulatory issues. In particular, while economic calculations 
do allow to predict a positive cost-benefit ratio – at least 
in some applications, as shown here – to the best of our 
knowledge, no specific reimbursement for coated 
implants is currently foreseen in European countries. on 
the other hand, a number of technologies are struggling 
in the pipeline, awaiting the long and expensively 
attained approval of regulatory bodies. while adverse 
events resulting from a new technology are promptly 
Table IV. Main effects of preventing post-surgical infection after joint arthroplasty according to various simulations
Authors (year) Baseline post-surgical 
infection rate in target 
population, %
expected infection 
reduction rate, %
estimated reduction in 
deep infections, n (cases 
per 100 000 procedures)
estimated annual cost 
savings per index procedure
Shearer et al77 (2015) 0.3 10.0 30 $98
Graves et al76 (2016) 2.4 87.0 1915 £108
Trentinaglia et al49 (2018) 2.0 80.0 1600 €200
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and widely reported, the opportunity cost following the 
delayed or denied introduction of potentially useful new 
products remains largely unknown to the public. This 
imbalance has led to an increasingly strict vision from 
policymakers and regulatory bodies concerning new 
medical device approval.
Given the potential benefits that can be anticipated sci-
entifically by a wider application of antibacterial implant-
coating technologies, in our opinion, effort should be 
made to increase the awareness of healthcare providers 
and their patients concerning the existing technologies 
and their possible contribution to mitigate septic compli-
cation. Furthermore, specific reimbursements for the cur-
rently available coatings should be introduced, with 
faster and more affordable regulatory pathways for the 
most promising technologies in the pipeline. at the same 
time, an efficient and independent post-marketing sur-
veillance system needs to be set at national or interna-
tional level, in order to monitor the clinical results and 
promptly report on any possible side effect or long-term 
complication of such new technologies.
Supplementary Material
The antibacterial coating cost impact calculation 
spreadsheet used to calculate the costs given in this 
study.
References
 1. Yin J, Luan S. Opportunities and challenges for the development of polymer-based 
biomaterials and medical devices. Regen Biomater 2016;3:129-135.
 2. Bhawsar N. Global Implantable Biomaterial Market Professional Survey Report 
2018. HTF Market Report Editors. https://www.htfmarketreport.com/reports/1266721-
global-implantable-biomaterial-market-1 (date last accessed 20 May 2019).
 3. Organisation for Economic Co-operation and Development (OECD), European 
Commission. Hip and knee replacement. In: Health at a Glance: Europe 2016: State 
of Health in the EU Cycle. Paris: OECD Publishing, 2016:172-173.
 4. Maradit Kremers H, Larson DR, Crowson CS, et al. Prevalence of total hip and 
knee replacement in the United States. J Bone Joint Surg [Am] 2015;97-A:1386-1397.
 5. Papin P, Berthonnaud E. Incidence of osteosynthesis of members in France. Int 
Orthop 2017;41:1501-1506.
 6. Cats-Baril W, Gehrke T, Huff K, et al. International consensus on periprosthetic 
joint infection: description of the consensus process. Clin Orthop Relat Res 
2013;471:4065-4075.
 7. Lenguerrand E, Whitehouse MR, Beswick AD, et al. Description of the rates, 
trends and surgical burden associated with revision for prosthetic joint infection 
following primary and revision knee replacements in England and Wales: an analysis 
of the National Joint Registry for England, Wales, Northern Ireland and the Isle of 
Man. BMJ Open 2017;7:e014056.
 8. Yoon HK, Cho SH, Lee DY, et  al. A review of the literature on culture-negative 
periprosthetic joint infection: epidemiology, diagnosis and treatment. Knee Surg Relat 
Res 2017;29:155-164.
 9. Bonnevialle P, Bonnomet F, Philippe R, et  al. Early surgical site infection in 
adult appendicular skeleton trauma surgery: a multicenter prospective series. Orthop 
Traumatol Surg Res 2012;98:684-689.
 10. Berbari EF, Osmon DR, Lahr B, et al. The Mayo prosthetic joint infection risk score: 
implication for surgical site infection reporting and risk stratification. Infect Control 
Hosp Epidemiol 2012;33:774-781.
 11. Heppert V. Acute Infections After Osteosynthesis. In: Bentley G, ed. European 
Instructional Lectures: Volume 12, 2012, 13th EFORT Congress, Berlin, Germany. 
Heidelberg: Springer-Verlag, 2012:25-31.
 12. Keene DJ, Mistry D, Nam J, et al. The Ankle Injury Management (AIM) trial: a 
pragmatic, multicentre, equivalence randomised controlled trial and economic 
evaluation comparing close contact casting with open surgical reduction and internal 
fixation in the treatment of unstable ankle fractures in patients aged over 60 years. 
Health Technol Assess 2016;20:1-158.
 13. Oliveira PR, Carvalho VC, da Silva Felix C, et  al. The incidence and 
microbiological profile of surgical site infections following internal fixation of closed 
and open fractures. Rev Bras Ortop 2016;51:396-399.
 14. Shillingford JN, Laratta JL, Reddy H, et al. Postoperative surgical site infection 
after spine surgery: an update from the Scoliosis Research Society (SRS) Morbidity 
and Mortality Database. Spine Deform 2018;6:634-643.
 15. Warner SJ, Uppstrom TJ, Miller AO, et al. Epidemiology of deep surgical site 
infections after pediatric spinal fusion surgery. Spine (Phila Pa 1976);2017;42:E163-
E168.
 16. Gupta R, Sood M, Malhotra A, et al. Incidence, risk factors, and management of 
infection following anterior cruciate ligament reconstruction surgery. Indian J Orthop 
2018;52:399-405.
 17. Kachooei AR, Baradaran A, Ebrahimzadeh MH, van Dijk CN, Chen N. The rate 
of radial head prosthesis removal or revision: a systematic review and meta-analysis. 
J Hand Surg Am 2018;43:39-53.e1.
 18. Brown TS, Salib CG, Rose PS, et  al. Reconstruction of the hip after resection 
of periacetabular oncological lesions: a systematic review. Bone Joint J 2018; 
100-B(1 Suppl A):22-30.
 19. Poultsides LA, Liaropoulos LL, Malizos KN. The socioeconomic impact of 
musculoskeletal infections. J Bone Joint Surg [Am] 2010;92-A:e13.
 20. Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J. Economic burden of 
periprosthetic joint infection in the United States. J Arthroplasty 2012;27(8 
Suppl):61-65.e1.
 21. Hernández-Vaquero D, Fernández-Fairen M, Torres A, et  al. Treatment of 
periprosthetic infections: an economic analysis. ScientificWorldJournal 2013; 
2013:821650.
 22. Garrido-Gómez J, Arrabal-Polo MA, Girón-Prieto MS, et  al. Descriptive 
analysis of the economic costs of periprosthetic joint infection of the knee for the 
public health system of Andalusia. J Arthroplasty 2013;28:1057-1060.
 23. Klouche S, Sariali E, Mamoudy P. Total hip arthroplasty revision due to infection: a 
cost analysis approach. Orthop Traumatol Surg Res 2010;96:124-132.
 24. Haenle M, Skripitz C, Mittelmeier W, Skripitz R. Economic impact of infected 
total knee arthroplasty. ScientificWorldJournal 2012;2012:196515.
 25. Lieb E, Hanstein T, Schuerings M, Trampuz A, Perka C. Reduction of treatment 
duration in periprosthetic infection with a fast-track concept is economically not 
feasible. Z Orthop Unfall 2015;153:618-623. (Article in German)
 26. Vanhegan IS, Malik AK, Jayakumar P, Ul Islam S, Haddad FS. A financial 
analysis of revision hip arthroplasty: the economic burden in relation to the national 
tariff. J Bone Joint Surg [Br] 2012;94-B:619-623.
 27. Alp E, Cevahir F, Ersoy S, Guney A. Incidence and economic burden of prosthetic 
joint infections in a university hospital: a report from a middle-income country. 
J Infect Public Health 2016;9:494-498.
 28. Kamath AF, Ong KL, Lau E, et  al. Quantifying the burden of revision total joint 
arthroplasty for periprosthetic infection. J Arthroplasty 2015;30:1492-1497.
 29. Romanò CL, Romanò D, Logoluso N, Meani E. Septic versus aseptic hip revision: 
how different? J Orthop Traumatol 2010;11:167-174.
 30. Parisi TJ, Konopka JF, Bedair HS. What is the long-term economic societal effect 
of periprosthetic infections after THA? A Markov analysis. Clin Orthop Relat Res 
2017;475:1891-1900.
 31. Brochin RL, Phan K, Poeran J, et al. Trends in periprosthetic hip infection and 
associated costs: a population-based study assessing the impact of hospital factors 
using national data. J Arthroplasty 2018;33:S233-S238.
 32. Gristina AG, Naylor P, Myrvik Q. Infections from biomaterials and implants: a race 
for the surface. Med Prog Technol 1988;14:205-224.
 33. Gristina AG, Shibata Y, Giridhar G, Kreger A, Myrvik QN. The glycocalyx, 
biofilm, microbes, and resistant infection. Semin Arthroplasty 1994;5:160-170.
 34. Dastgheyb S, Parvizi J, Shapiro IM, Hickok NJ, Otto M. Effect of biofilms on 
recalcitrance of staphylococcal joint infection to antibiotic treatment. J Infect Dis 
2015;211:641-650.
 35. Holá V, Ru˚žicˇka F, Votava M. The dynamics of staphylococcus epidermis biofilm 
formation in relation to nutrition, temperature, and time. Scr Med (Brno) 2006;79: 
169-174.
 36. Chandki R, Banthia P, Banthia R. Biofilms: a microbial home. J Indian Soc 
Periodontol 2011;15:111-114.
 37. Thornley P, Evaniew N, Riediger M, et al. Postoperative antibiotic prophylaxis in 
total hip and knee arthroplasty: a systematic review and meta-analysis of randomized 
controlled trials. CMAJ Open 2015;3:E338-E343.
205aNTIBaCTERIal CoaTING oF IMPlaNTS: aRE wE MISSING SoMETHING? 
vol. 8, No. 5, May 2019
 38. Qin S, Xu K, Nie B, Ji F, Zhang H. Approaches based on passive and active 
antibacterial coating on titanium to achieve antibacterial activity. J Biomed Mater 
Res A 2018;106:2531-2539.
 39. Itabashi T, Narita K, Ono A, et al. Bactericidal and antimicrobial effects of pure 
titanium and titanium alloy treated with short-term, low-energy UV irradiation. Bone 
Joint Res 2017;6:108-112.
 40. Romanò CL, Scarponi S, Gallazzi E, Romanò D, Drago L. Antibacterial coating 
of implants in orthopaedics and trauma: a classification proposal in an evolving 
panorama. J Orthop Surg Res 2015;10:157.
 41. Moriarty TF, Grainger DW, Richards RG. Challenges in linking preclinical anti-
microbial research strategies with clinical outcomes for device-associated infections. 
Eur Cell Mater 2014;28:112-128.
 42. Alt V. Antimicrobial coated implants in trauma and orthopaedics-a clinical review and 
risk-benefit analysis. Injury 2017;48:599-607.
 43. Chernousova S, Epple M. Silver as antibacterial agent: ion, nanoparticle, and 
metal. Angew Chem Int Ed Engl 2013;52:1636-1653.
 44. Schmidt-Braekling T, Streitbuerger A, Gosheger G, et  al. Silver-coated 
megaprostheses: review of the literature. Eur J Orthop Surg Traumatol 2017;27:483-
489.
 45. Hardes J, von Eiff C, Streitbuerger A, et al. Reduction of periprosthetic infection 
with silver-coated megaprostheses in patients with bone sarcoma. J Surg Oncol 
2010;101:389-395.
 46. Hardes J, Henrichs MP, Hauschild G, et al. Silver-coated megaprosthesis of the 
proximal tibia in patients with sarcoma. J Arthroplasty 2017;32:2208-2213.
 47. Wafa H, Grimer RJ, Reddy K, et al. Retrospective evaluation of the incidence of 
early periprosthetic infection with silver-treated endoprostheses in high-risk patients: 
case-control study. Bone Joint J 2015;97-B:252-257.
 48. Mijnendonckx K, Leys N, Mahillon J, Silver S, van Houdt R. Antimicrobial 
silver: uses, toxicity and potential for resistance. Biometals 2013;26:609-621.
 49. Trentinaglia MT, Van Der Straeten C, Morelli I, et  al. Economic evaluation 
of antibacterial coatings on healthcare costs in first year following total joint 
arthroplasty. J Arthroplasty 2018;33:1656-1662.
 50. Shirai T, Shimizu T, Ohtani K, et  al. Antibacterial iodine-supported titanium 
implants. Acta Biomater 2011;7:1928-1933.
 51. Inoue D, Kabata T, Ohtani K, et  al. Inhibition of biofilm formation on iodine-
supported titanium implants. Int Orthop 2017;41:1093-1099.
 52. Inoue D, Kabata T, Kajino Y, Shirai T, Tsuchiya H. Iodine-supported titanium 
implants have good antimicrobial attachment effects. J Orthop Sci 2018. (Epub ahead 
of print) PMID: 30409704.
 53. Tsuchiya H, Shirai T, Nishida H, et al. Innovative antimicrobial coating of titanium 
implants with iodine. J Orthop Sci 2012;17:595-604.
 54. Shirai T, Tsuchiya H, Nishida H, et al. Antimicrobial megaprostheses supported 
with iodine. J Biomater Appl 2014;29:617-623.
 55. Kabata T, Maeda T, Kajino Y, et  al. Iodine-supported hip implants: short term 
clinical results. BioMed Res Int 2015;2015:368124.
 56. Schmidmaier G, Wildemann B, Stemberger A, Haas NP, Raschke M. Bio-
degradable poly(D, L-lactide) coating of implants for continuous release of growth 
factors. J Biomed Mater Res 2001;58:449-455.
 57. Fuchs T, Stange R, Schmidmaier G, Raschke MJ. The use of gentamicin-coated 
nails in the tibia: preliminary results of a prospective study. Arch Orthop Trauma Surg 
2011;131:1419-1425.
 58. Metsemakers WJ, Reul M, Nijs S. The use of gentamicin-coated nails in complex 
open tibia fracture and revision cases: a retrospective analysis of a single centre case 
series and review of the literature. Injury 2015;46:2433-2437.
 59. Schmidmaier G, Kerstan M, Schwabe P, Südkamp N, Raschke M. Clinical 
experiences in the use of a gentamicin-coated titanium nail in tibia fractures. Injury 
2017;48:2235-2241.
 60. Schmitz FJ, Verhoef J, Fluit AC. Prevalence of aminoglycoside resistance in 20 
European university hospitals participating in the European SENTRY Antimicrobial 
Surveillance Programme. Eur J Clin Microbiol Infect Dis 1999;18:414-421.
 61. Drago L, Boot W, Dimas K, et al. Does implant coating with antibacterial-loaded 
hydrogel reduce bacterial colonization and biofilm formation in vitro? Clin Orthop 
Relat Res 2014;472:3311-3323.
 62. Romanò CL, De Vecchi E, Bortolin M, Morelli I, Drago L. Hyaluronic acid and its 
composites as a local antimicrobial/antiadhesive barrier. J Bone Jt Infect 2017;2:63-72.
 63. Ardizzoni A, Neglia RG, Baschieri MC, et  al. Influence of hyaluronic acid on 
bacterial and fungal species, including clinically relevant opportunistic pathogens. 
J Mater Sci Mater Med 2011;22:2329-2338.
 64. Pavesio A, Renier D, Cassinelli C, Morra M. Anti-adhesive surfaces through 
hyaluronan coatings. Med Device Technol 1997;8:20-21, 24-27.
 65. Morra M, Cassineli C. Non-fouling properties of polysaccharide-coated surfaces. J 
Biomater Sci Polym Ed 1999;10:1107-1124.
 66. Cassinelli C, Morra M, Pavesio A, Renier D. Evaluation of interfacial properties 
of hyaluronan coated poly(methylmethacrylate) intraocular lenses. J Biomater Sci 
Polym Ed 2000;11:961-977.
 67. Kadry AA, Fouda SI, Shibl AM, Abu El-Asrar AA. Impact of slime dispersants and 
anti-adhesives on in vitro biofilm formation of Staphylococcus epidermidis on intraocular 
lenses and on antibiotic activities. J Antimicrob Chemother 2009;63:480-484.
 68. Junter GA, Thébault P, Lebrun L. Polysaccharide-based antibiofilm surfaces. Acta 
Biomater 2016;30:13-25.
 69. Giavaresi G, Meani E, Sartori M, et al. Efficacy of antibacterial-loaded coating in 
an in vivo model of acutely highly contaminated implant. Int Orthop 2014;38:1505-
1512.
 70. Boot W, Vogely HCh, Nikkels PGJ, et  al. Local prophylaxis of implant-related 
infections using a hydrogel as carrier. Eur Cell Mater 2015;30(Suppl 2):19.
 71. Boot W, Gawlitta D, Nikkels PGJ, et al. Hyaluronic acid-based hydrogel coating 
does not affect bone apposition at the implant surface in a rabbit model. Clin Orthop 
Relat Res 2017;475:1911-1919.
 72. Romanò CL, Malizos K, Capuano N, et  al. Does an antibiotic-loaded hydrogel 
coating reduce early post-surgical infection after joint arthroplasty? J Bone Jt Infect 
2016;1:34-41.
 73. Malizos K, Blauth M, Danita A, et al. Fast-resorbable antibiotic-loaded hydrogel 
coating to reduce post-surgical infection after internal osteosynthesis: a multicenter 
randomized controlled trial. J Orthop Traumatol 2017;18:159-169.
 74. Capuano N, Logoluso N, Gallazzi E, Drago L, Romanò CL. One-stage exchange 
with antibacterial hydrogel coated implants provides similar results to two-stage 
revision, without the coating, for the treatment of peri-prosthetic infection. Knee Surg 
Sports Traumatol Arthrosc 2018;26:3362-3367.
 75. Zagra L, Gallazzi E, Romanò D, Scarponi S, Romanò C. Two-stage cementless 
hip revision for peri-prosthetic infection with an antibacterial hydrogel coating: 
results of a comparative series. Int Orthop. 2019;43:111-115.
 76. Graves N, Wloch C, Wilson J, et  al. A cost-effectiveness modelling study of 
strategies to reduce risk of infection following primary hip replacement based on a 
systematic review. Health Technol Assess 2016;20:1-144.
 77. Shearer DW, Youm J, Bozic KJ. Short-term complications have more effect on cost-
effectiveness of THA than implant longevity. Clin Orthop Relat Res 2015;473:1702-
1708.
 78. Parvizi J, Pawasarat IM, Azzam KA, et  al. Periprosthetic joint infection: the 
economic impact of methicillin-resistant infections. J Arthroplasty 2010;25(6 
Suppl):103-107.
 79. Berend KR, Lombardi AV Jr, Morris MJ, et  al. Two-stage treatment of hip 
periprosthetic joint infection is associated with a high rate of infection control but 
high mortality. Clin Orthop Relat Res 2013;471:510-518.
 80. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip 
and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg [Am] 
2007;89-A:780-785.
 81. Kurtz SM, Ong KL, Schmier J, et al. Future clinical and economic impact of revision 
total hip and knee arthroplasty. J Bone Joint Surg [Am] 2007;89-A(Suppl 3):144-151.
Author contributions
  C. l. Romanò: wrote the manuscript.
  H. Tsuchiya: Edited the manuscript.
  I. Morelli: Reviewed the literature, Edited the manuscript.
  a. G. Battaglia: Reviewed the literature, Edited the manuscript.
  l. Drago: Reviewed the literature, Edited the manuscript.
Funding statement
  The author or one or more of the authors have received or will receive benefits for 
personal or professional use from a commercial party related directly or indirectly 
to the subject of this article.
conflict of interest statement
  C. l. Romanò co-patented the technology underlying the Defensive antibacterial 
Coating (DaC). C. l. Romanò also reports consultancy fees from link Italia and 
adlerortho, as well as payment for lectures from DePuy Synthes and royalties from 
Novagenit, none of which are related to this study.
© 2019 Author(s) et al. This is an open-access article distributed under the terms 
of the Creative Commons attributions licence (CC-By-NC), which permits unrestricted 
use, distribution, and reproduction in any medium, but not for commercial gain, pro-
vided the original author and source are credited.
